Navigation Links
Steroids Provide No Survival Benefit for Children With Bacterial Meningitis
Date:5/6/2008

-Large Study Shows Benefits Differ from those in Adults-

PHILADELPHIA, May 6 /PRNewswire-USNewswire/ -- Corticosteroids given to children who are hospitalized for bacterial meningitis do not provide a benefit in survival or in reduced hospital stays, according to a large multicenter study by pediatric researchers. This finding stands in contrast to previous studies in hospitalized adults, for whom corticosteroids dramatically reduced mortality.

"Because of the demonstrated benefits of these drugs in adults, physicians have increasingly been using corticosteroids in children with bacterial meningitis," said study leader Samir S. Shah, M.D., an infectious diseases specialist from The Children's Hospital of Philadelphia. "This study reminds us again that children are not just small adults. We need to consider whether the problems associated with corticosteroid use, such as gastrointestinal bleeding, outweigh any potential benefits."

He added that further research should analyze whether corticosteroids may provide other benefits to children, such as improved neurological outcomes among survivors, a question not considered in this study.

The study appears in the May 7 issue of the Journal of the American Medical Association.

Shah's team analyzed medical records of 2,780 children with bacterial meningitis at 27 U.S. pediatric hospitals from 2001 to 2006. The median age of the children was nine months. Approximately 9 percent, or 248, of the children studied received corticosteroids, with steroid use doubling during the study period, from under 6 percent of children in 2001 to 12 percent in 2006.

There was no significant difference in mortality nor in time to hospital discharge, between children who received corticosteroids and those who did not. Overall, unadjusted mortality rates were 6 percent among children receiving corticosteroids, versus 4 percent among those not receiving them. There also was no significant difference in those outcomes between those receiving and not receiving corticosteroids in the subsets of children with meningitis caused by pneumococcal bacteria or by meningococcal bacteria.

Meningitis is an inflammation of the meninges, the membrane lining the brain. The bacterial form is relatively rare in children, with an incidence of about eight in 100,000 in the U.S. However, bacterial meningitis is potentially life-threatening, and requires hospitalization and treatment with antibiotics. Several different varieties of bacteria may cause meningitis, although the patterns have changed with the introduction of vaccines.

Previous studies had shown that corticosteroids had a clear benefit in preventing hearing loss in children whose meningitis was caused by Hemophilus influenzae type b (Hib) bacteria. However, since the Hib vaccine was approved for routine use in childhood immunizations in 1985, cases of Hib meningitis have dropped sharply in the United States. Now bacterial meningitis in children is more commonly caused by pneumococcal or meningococcal bacteria.

Further studies may reveal that corticosteroids may also reduce hearing loss or other neurologic injuries in children with bacterial meningitis not caused by Hib, said Shah, but there is currently no such evidence. He added, "Our study shows the need for a further study in children -- a large randomized clinical trial to examine all outcomes of steroid use, before the use of these medicines becomes routine in children with bacterial meningitis."

The National Center for Research Resources, part of the National Institutes of Health, supported the study, along with the Agency for Healthcare Research and Quality. One co-author, Jillian Mongelluzzo, received support from the Doris Duke Medical Student Clinical Research Fellowship. Shah's other co-authors were Zeinab Mohamad, M.S., from Children's Hospital, and Thomas R. Ten Have, Ph.D., from the University of Pennsylvania School of Medicine.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.

Contact: Rachel Salis-Silverman

Phone: (267) 426-6063

Salis@email.chop.edu


'/>"/>
SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
2. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
3. Gene Therapy Provides Vision to People who Were Nearly Blind
4. Arpida Provides Further Comments on the Pivotal Phase III Trials
5. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
6. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
7. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
8. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
9. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
10. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
11. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology:
(Date:4/30/2017)... Viejo, CA (PRWEB) , ... April 30, 2017 ... ... animations created exclusively for use in Final Cut Pro X. Editors can pick ... and more. Easily change the highlights, mid levels and shadows using simple color ...
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of ... video to the next without having to set a single keyframe in Final ... enhance your video production. , TransDark features dynamic transitions that momentarily splits the RGB ...
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty ... pounds with the help of a weight loss surgery. The woman, declaring “I will not ... have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
Breaking Medicine News(10 mins):